Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

LGND

BUY

Ligand Pharmaceuticals Incorporated · Healthcare · United States · $6.0B · Avg Vol: $147M/d

75
StockRank
Get insider-trade alerts
Q
67
V
23
M
79
P/E (TTM)
39.5x
ROE
17.1%
D/E
0.5x
Dividend %
—
Dir. Trades · 180d
−$11.4M →
Buybacks · 180d
None →

COMPANY DESCRIPTION

Ligand Pharmaceuticals Incorporated operates a unique royalty-based business model, focusing on developing and licensing proprietary drug discovery and development platforms to pharmaceutical partners. Its primary competitive moat is built around its patented Captisol® technology, which significantly enhances drug solubility and stability, making it a crucial component in numerous approved and pipeline drug products. This intellectual property-centric approach generates revenue through royalties on partners' sales rather than costly direct drug development.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue196.2M131.3M167.1M268.1M11.0%274.5M289.8M375.4M18.3%
EPS-1.983.02-0.226.4446.0%7.457.289.3720.6%
Shares17.0M17.6M19.1M19.8M+16.7%20.0M———
Debt87.7M6.2M7.1M451.5M72.6%452.0M———
Equity597.5M700.9M830.4M1.0B19.4%————
Op CF137.8M49.6M97.0M49.4M-29.0%123.5M———
Inv CF163.6M-11.7M-143.7M-377.3M—————
Fin CF-276.0M-59.9M97.1M428.2M—————
Loading 1Y...
PRICE (1Y)+18.1%
253271288305323Jun 11Jul 6Jul 24
SMA 50SMA 200
Close
$300.53
RSI (14)
36.3
52W High
$326.63
From 52W High
0.9%

SCORE BREAKDOWN

Quality
67
ROIC
10.7%76.1
ROE
17.1%85.7
GP/Assets
14.6%35.8
Op. Margin
33.6%94.3
FCF/Assets
9.1%84.6
Piotroski
550.0
Int. Cover
34.7x75.1
D/E Ratio
0.45x32.5
Current Ratio
21.28x95.9
Value
23
P/E (TTM)
39.5x27.9
EV/EBITDA
41.4x13.5
P/FCF
42.4x30.7
P/B
5.9x22.7
P/S
21.5x16.4
Div Yield
—N/A
Momentum
79
52W High %
92%90.2
RS 6M
40%92.1
SMA 50/200
1.23x91.4
EPS Rev 4W
+2.5%89.3
EPS Rev 12W
+16.8%91.0
EPS Improve
+56%57.8
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$6.0B
P/E (Forward)
25.3x
Gross Margin
83.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LGND are excluded.

TickerCompanyMkt CapStockRankSignal
LGNDLigand Pharmaceuticals Incorporated(you)$6.0B75BUY
0I3Q.LCorcept Therapeutics Incorporated$5.7B74BUY
KRYSKrystal Biotech, Inc.$9.9B72BUY
BMRNBioMarin Pharmaceutical Inc.$11.5B72BUY
TGTXTG Therapeutics, Inc.$8.6B85STRONG BUY
TECHBio-Techne Corporation$11.2B67BUY
ACADACADIA Pharmaceuticals Inc.$4.3B60HOLD
0J2O.LHalozyme Therapeutics, Inc.$14.6B80STRONG BUY
0KHE.LRevvity, Inc.$13.6B68BUY
0K6R.LNeurocrine Biosciences, Inc.$16.9B80BUY

Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%

Ligand Pharmaceuticals Incorporated (LGND) — Stock Score Summary

Ligand Pharmaceuticals Incorporated (LGND) has a MoatMap StockRank of 75/100 based on Quality (67/100), Value (23/100), and Momentum (79/100) factor scores. The current signal is BUY.

Ligand Pharmaceuticals Incorporated operates a unique royalty-based business model, focusing on developing and licensing proprietary drug discovery and development platforms to pharmaceutical partners. Its primary competitive moat is built around its patented Captisol® technology, which significantly enhances drug solubility and stability, making it a crucial component in numerous approved and pipeline drug products. This intellectual property-centric approach generates revenue through royalties on partners' sales rather than costly direct drug development.

Key Financial Metrics

Price$300.53
Market Cap$6.0B
P/E (TTM)39.46
P/E (Forward)25.34
Price/Book5.90
Return on Equity17.1%
Return on Invested Capital10.7%
Debt/Equity0.45x
Gross Margin83.2%
Operating Margin33.6%
Revenue Growth14.1%
Free Cash Flow$142M

Ligand Pharmaceuticals Incorporated operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Ligand Pharmaceuticals Incorporated’s (LGND) StockRank?
MoatMap’s StockRank for Ligand Pharmaceuticals Incorporated (LGND) is 75/100, with a Buy signal. It is a composite of Quality (67), Value (23), and Momentum (79) factor ranks across MoatMap’s 20,000+ stock universe.
Does Ligand Pharmaceuticals Incorporated have an economic moat?
Ligand Pharmaceuticals Incorporated (LGND) has a Quality factor score of 67/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Ligand Pharmaceuticals Incorporated a buy, hold, or sell?
MoatMap’s current signal for Ligand Pharmaceuticals Incorporated (LGND) is Buy, based on a StockRank of 75/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Ligand Pharmaceuticals Incorporated in?
Ligand Pharmaceuticals Incorporated (LGND) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksLGND deep dive reportAI ChampionsHow we score stocksSense-check another stock